Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This online program is recorded content from the live session at Rural Health Clinical Congress Spring 2023 and is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

Program Overview

Asthma places a significant burden on individuals in rural and underserved communities, where access to general care and specialty services is limited. Often, patients must travel long distances to be seen by a healthcare professional, placing them at higher risk for poor health outcomes. In addition, primary care clinicians in these settings may not be familiar with the latest advances in our understanding of asthma or how to manage patients with severe, uncontrolled disease. In this activity, expert faculty will review best practices for asthma assessment and monitoring, updated guideline recommendations for management, and available biologic therapies for severe asthma. Strategies for reducing disparities in care and optimizing patient outcomes in rural and underserved communities will also be discussed. 

This enduring activity is a recorded session from Rural Health Clinical Congress Spring 2023 that took place on May 20, 2023.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Integrate the latest guidance into the care of patients with moderate-to-severe asthma
• Develop evidence-based treatment plans for patients with moderate-to-severe asthma that consider exacerbation risks, comorbidities, and quality of life
• Apply strategies including self-management education and asthma action plans to improve asthma care and management in rural and underserved settings

Faculty

Wanda Phipatanakul, MD, MS
S. Jean Emans Professor of Pediatrics
Harvard Medical School
Attending Physician and Director, Clinical Research Center
Division of Immunology
Boston Children's Hospital
Boston, MA

Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Wanda Phipatanakul, MD, MS, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., and Sanofi.

Barbara P. Yawn, MD, MSc, FAAFP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Pulmonx, and Teva Pharmaceuticals; contracted research for AstraZeneca Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, and Teva Pharmaceuticals.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.